Zhu Menglin, Wang Zhixiong, He Yiren, Zhang Bo, Wu Longfei, Liu Cai, Fei Yao, Gao Peng, Cai Juan, Zuo Xueliang
Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China; Department of General Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu 241001, China.
Department of General Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu 241001, China.
J Adv Res. 2025 Jun 6. doi: 10.1016/j.jare.2025.06.008.
Immunotherapy, especially anti-PD-1 antibodies (α-PD-1), has revolutionized the landscape of cancer treatment. However, the response rate of α-PD-1 for Gastric Cancer (GC) remains relatively low. The acidic immunosuppressive Tumor Microenvironment (TME) greatly hinders the efficacy of α-PD-1. Thus, therapeutic strategies targeting the acidic TME in GC are highly desired.
This study aimed to investigate the effect of FX-11@PEG-Ce6 on the therapeutic efficacy of photoimmunotherapy for gastric cancer.
We developed FX-11 encapsulated with PEG-Ce6 nanoparticles (FX-11@PEG-Ce6) for GC photoimmunotherapy. The morphology was observed by transmission electron microscopy. Flow cytometry was performed to detect the maturation level of dendritic cells and the levels of TNF-α, IFN-γ, and granzyme B in CD8 T cells, and to evaluate the synergistic anti-tumor effects of photoimmunotherapy generated by FX-11@PEG-Ce6 in combination with α-PD-1 in vitro and in vivo. The biological safety of FX-11@PEG-Ce6 was studied by haematoxylin and eosin staining and biochemical analysis of major organs.
As a type of nanoplatform, FX-11@PEG-Ce6 demonstrated satisfactory cellular uptake and tumor targeting ability. FX-11@PEG-Ce6 provoked significant immunogenic cell death response. Meanwhile, the results of flow cytometry showed that FX-11@PEG-Ce6 facilitated the maturation of dendritic cells and augmented the secretion of T-cell cytokines. Through the detection of the pH of the cell culture medium, it was revealed that FX-11@PEG-Ce6 could alleviate the acidity of the TME, thereby restoring the function of T cells and enhancing the anti-tumor activity of CD8 T cells. MFC tumor-bearing mouse models were adopted. In vivo results showed that FX-11@PEG-Ce6 could alleviate the acidic TME and help eradicate tumor cells. FX-11@PEG-Ce6 substantially enhance the efficacy of α-PD-1 and exhibit superior biocompatibility.
Our results revealed that the combination of FX-11@PEG-Ce6-based photodynamic therapy and immunotherapy could achieve a synergistic antitumor effect with excellent biosafety, presenting great therapeutic potential for enhanced photoimmunotherapy for GC.
免疫疗法,尤其是抗程序性死亡蛋白1(PD-1)抗体(α-PD-1),已经彻底改变了癌症治疗的格局。然而,α-PD-1对胃癌(GC)的应答率仍然相对较低。酸性免疫抑制性肿瘤微环境(TME)极大地阻碍了α-PD-1的疗效。因此,非常需要针对GC中酸性TME的治疗策略。
本研究旨在探讨FX-11@PEG-Ce6对胃癌光免疫治疗疗效的影响。
我们开发了用聚乙二醇化二氢卟吩e6(PEG-Ce6)纳米颗粒包裹的FX-11(FX-11@PEG-Ce6)用于GC光免疫治疗。通过透射电子显微镜观察其形态。进行流式细胞术以检测树突状细胞的成熟水平以及CD8 T细胞中肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)和颗粒酶B的水平,并评估FX-11@PEG-Ce6与α-PD-1联合在体外和体内产生的光免疫治疗的协同抗肿瘤作用。通过苏木精和伊红染色以及主要器官的生化分析研究FX-11@PEG-Ce6的生物安全性。
作为一种纳米平台,FX-11@PEG-Ce6表现出令人满意的细胞摄取和肿瘤靶向能力。FX-11@PEG-Ce6引发了显著的免疫原性细胞死亡反应。同时,流式细胞术结果表明FX-11@PEG-Ce6促进了树突状细胞的成熟并增强了T细胞细胞因子的分泌。通过检测细胞培养基的pH值,发现FX-11@PEG-Ce6可以减轻TME的酸度,从而恢复T细胞的功能并增强CD8 T细胞的抗肿瘤活性。采用小鼠前胃癌(MFC)荷瘤模型。体内结果表明FX-11@PEG-Ce6可以减轻酸性TME并有助于根除肿瘤细胞。FX-11@PEG-Ce6显著增强了α-PD-1的疗效并表现出优异的生物相容性。
我们的结果表明,基于FX-11@PEG-Ce6的光动力疗法和免疫疗法的联合可以实现协同抗肿瘤作用,具有优异的生物安全性,为增强GC的光免疫治疗展现出巨大的治疗潜力。